Comparative Pharmacology
Head-to-head clinical analysis: ACETAMINOPHEN ASPIRIN AND CAFFEINE versus MEFENAMIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETAMINOPHEN ASPIRIN AND CAFFEINE versus MEFENAMIC ACID.
ACETAMINOPHEN, ASPIRIN AND CAFFEINE vs MEFENAMIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen: weak COX-1/2 inhibitor, analgesic and antipyretic through central action; Aspirin: irreversible COX-1/2 inhibitor, anti-inflammatory, analgesic, antipyretic, antiplatelet; Caffeine: adenosine receptor antagonist, CNS stimulant, enhances analgesic effect.
Reversible inhibition of cyclooxygenase (COX-1 and COX-2) leading to decreased prostaglandin synthesis; exhibits both central and peripheral analgesic effects.
1-2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine per tablet) orally every 4-6 hours as needed for pain or fever; maximum 8 tablets per 24 hours.
500 mg orally as an initial dose, followed by 250 mg every 6 hours as needed, not to exceed 1 week.
None Documented
None Documented
Acetaminophen: 2-4 hours (prolonged in liver disease); aspirin: 15-20 minutes (active metabolite salicylate: 2-3 hours at low doses, prolonged to 15-30 hours at high doses); caffeine: 3-6 hours (prolonged in pregnancy, liver disease).
Terminal half-life is 2-4 hours; prolonged in hepatic impairment and overdose.
Acetaminophen: renal elimination of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%, unchanged 2%); aspirin: renal elimination of salicylate and metabolites (75% salicyluric acid, 10% glucuronides, 10% salicylate); caffeine: renal elimination of metabolites (paraxanthine, theobromine, theophylline; <3% unchanged). Total: >95% renal.
Primarily renal (52% as glucuronide metabolites, <6% unchanged) and fecal (20-30% via biliary elimination).
Category D/X
Category D/X
NSAID / Antiplatelet
NSAID